[go: up one dir, main page]

MX2019007021A - Anticuerpos il-11ra. - Google Patents

Anticuerpos il-11ra.

Info

Publication number
MX2019007021A
MX2019007021A MX2019007021A MX2019007021A MX2019007021A MX 2019007021 A MX2019007021 A MX 2019007021A MX 2019007021 A MX2019007021 A MX 2019007021A MX 2019007021 A MX2019007021 A MX 2019007021A MX 2019007021 A MX2019007021 A MX 2019007021A
Authority
MX
Mexico
Prior art keywords
antibodies
disclosed
compositions
methods
Prior art date
Application number
MX2019007021A
Other languages
English (en)
Inventor
Alexander Cook Stuart
Schaefer Sebastian
Original Assignee
Singapore Health Serv Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Singapore Health Serv Pte Ltd filed Critical Singapore Health Serv Pte Ltd
Publication of MX2019007021A publication Critical patent/MX2019007021A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5431—IL-11
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se divulgan los anticuerpos IL-11Ra. Tambien se divulgan son composiciones que comprenden anticuerpos IL-11Ra y los metodos de uso de anticuerpos IL-11Ra.
MX2019007021A 2016-12-16 2017-12-15 Anticuerpos il-11ra. MX2019007021A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1621439.7A GB201621439D0 (en) 2016-12-16 2016-12-16 IL-11Ra Antibodies
PCT/EP2017/083043 WO2018109170A2 (en) 2016-12-16 2017-12-15 Il-11ra antibodies

Publications (1)

Publication Number Publication Date
MX2019007021A true MX2019007021A (es) 2019-10-21

Family

ID=58284610

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019007021A MX2019007021A (es) 2016-12-16 2017-12-15 Anticuerpos il-11ra.

Country Status (12)

Country Link
US (2) US20180186872A1 (es)
EP (1) EP3555135B1 (es)
JP (1) JP7175271B2 (es)
KR (1) KR20190111924A (es)
CN (1) CN110337447B (es)
AU (1) AU2017378107A1 (es)
BR (1) BR112019012343A2 (es)
CA (1) CA3046848A1 (es)
GB (1) GB201621439D0 (es)
MX (1) MX2019007021A (es)
TW (1) TW201829465A (es)
WO (1) WO2018109170A2 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201522186D0 (en) 2015-12-16 2016-01-27 Singapore Health Services Pte Ltd And Nat University Of Singapore The Treatment of fibrosis
GB201621439D0 (en) 2016-12-16 2017-02-01 Singapore Health Services Pte Ltd And Nat Univ Of Singapore IL-11Ra Antibodies
US20180186871A1 (en) 2016-12-16 2018-07-05 Singapore Health Services Pte Ltd. Il-11 antibodies
GB201809700D0 (en) * 2018-06-13 2018-08-01 Singapore Health Serv Pte Ltd IL-11 antibodies
CN109053882B (zh) * 2018-08-28 2019-08-23 东莞市朋志生物科技有限公司 一种ns1蛋白的结合蛋白以及应用
AU2020211695A1 (en) 2019-01-21 2021-09-02 National University Of Singapore Treatment of hepatotoxicity
GB201902419D0 (en) 2019-02-22 2019-04-10 Singapore Health Serv Pte Ltd Treatment of kidney injury
GB201906291D0 (en) 2019-05-03 2019-06-19 Singapore Health Serv Pte Ltd Treatment and prevention of metabolic diseases
AU2020268619A1 (en) 2019-05-03 2021-12-16 National University Of Singapore Treatment and prevention of metabolic diseases
RU2722398C1 (ru) * 2019-08-09 2020-05-29 Федеральное государственное унитарное предприятие «Государственный научно-исследовательский институт особо чистых биопрепаратов» Федерального медико-биологического агентства Моноклональное антитело к БТШ70
GB202009292D0 (en) 2020-06-18 2020-08-05 Singapore Health Serv Pte Ltd Treatment and prevention of disease caused by type IV collagen dysfunction
GB202017244D0 (en) 2020-10-30 2020-12-16 Nat Univ Singapore Methods to extend health-span and treat age-related diseases
CN116981691A (zh) * 2020-11-23 2023-10-31 斯克奥特比奥股份有限公司 抗原结合分子及其用途
JP2024512279A (ja) 2021-02-26 2024-03-19 バイエル アクチェンゲゼルシャフト 異常子宮出血の処置における使用のためのｉｌ－１１又はｉｌ－１１ｒａの阻害剤
JP2024526944A (ja) 2021-07-26 2024-07-19 ベーリンガー・インゲルハイム・インターナショナル・ゲーエムベーハー アルコール性肝疾患の処置および予防
IL311043A (en) 2021-08-30 2024-04-01 Lassen Therapeutics 1 Inc Anti-il-11rα antibodies
CN113735975B (zh) * 2021-09-07 2022-08-12 广东东阳光药业有限公司 一种抗il-11r抗体及其应用
WO2023111196A1 (en) 2021-12-16 2023-06-22 Singapore Health Services Pte. Ltd. Treatment and prevention of glomerular disease
CN116510007A (zh) * 2022-01-29 2023-08-01 迈威(上海)生物科技股份有限公司 采用抗il-11抗体的肿瘤组合疗法
WO2024148240A1 (en) * 2023-01-06 2024-07-11 Lassen Therapeutics 1, Inc. ANTI-IL-11Rα ANTIBODIES FOR TREATING THYROID EYE DISEASE
WO2025255483A2 (en) * 2024-06-07 2025-12-11 Lassen Therapeutics, Inc. DOSING OF ANTI-IL-11Rα ANTIBODIES IN THE TREATMENT OF THYROID EYE DISEASE
WO2025255486A2 (en) * 2024-06-07 2025-12-11 Lassen Therapeutics, Inc. DOSING OF ANTI-IL-11Rα ANTIBODIES IN THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10511266A (ja) 1994-12-22 1998-11-04 ジェネティックス・インスティテュート・インコーポレイテッド ヒト・インターロイキン−１１受容体
US6540993B1 (en) 1995-06-27 2003-04-01 Wyeth Method of treating inflammatory bowel disease using a topical formulation of IL-11
US6126933A (en) 1995-06-27 2000-10-03 Genetics Institute Methods of treating inflammatory bowel diseases by administering IL-11
US5679339A (en) 1995-06-27 1997-10-21 Keith; James Method of using IL-11 for treating spondyloarthropies
GB9702944D0 (en) 1997-02-13 1997-04-02 Univ Manchester Reducing fibrosis
GB9721961D0 (en) 1997-10-16 1997-12-17 Glaxo Group Ltd Novel molecules
CA2237915A1 (en) 1998-05-19 1999-11-19 Stephen Shaughnessy Osteoporosis treatment
US6953777B2 (en) 1999-03-11 2005-10-11 Genetics Indtitute LLC Use of interleukin-11 to prevent immune-mediated cytotoxicity
AU5756100A (en) 1999-06-21 2001-01-09 Genetics Institute Inc. Treatment of fibrosis by antagonism of il-13 and il-13 receptor chains
GB0021668D0 (en) 2000-09-04 2000-10-18 Smithkline Beecham Plc New use
AU2003296413A1 (en) 2002-09-16 2004-04-30 Wyeth Delayed release formulations for oral administration of a polypeptide therapeutic agent and methods of using same
EP1709074A4 (en) 2003-12-16 2008-06-11 Commw Scient Ind Res Org CYTOKIN BINDING DOMAINS
WO2005070446A1 (en) 2004-01-15 2005-08-04 Scios Inc. Method for treating cardiac remodeling following myocardial injury
US20080300147A1 (en) 2004-03-26 2008-12-04 Nasser Chegini Detection and Treatment of Fibrotic Disorders
PT1630232E (pt) 2004-08-27 2008-10-02 Conaris Res Inst Ag Sequências de nucleótidos optimizadas que codificam sgp130
BRPI0619476A2 (pt) 2005-12-05 2011-10-04 Wyeth Corp composições de interleucina-11 e métodos de uso
CN100441689C (zh) * 2006-01-20 2008-12-10 中国人民解放军第三军医大学 抗ehec o157志贺样毒素ⅱa亚单位单克隆抗体5f3轻、重链可变区基因及应用
JP5191393B2 (ja) 2006-10-27 2013-05-08 国立大学法人大阪大学 インターロイキン１１の心疾患治療薬としての利用
CA2703544C (en) 2007-10-26 2016-01-05 Manuel Baca Cytokine muteins
US8182814B2 (en) 2007-10-26 2012-05-22 Csl Limited Methods of treating inflammatory airway conditions by inhibition of IL-11 activity
US8518888B2 (en) 2008-10-14 2013-08-27 Csl Limited Method of treatment of gastrointestinal-type cancer with antagonistic antibodies to IL-11R
KR101133769B1 (ko) 2011-04-18 2012-04-09 한국생명공학연구원 신규한 옥사졸리딘계 및 인돌계 화합물, 이의 제조방법 및 이를 포함하는 약학 조성물
SG11201505762XA (en) 2013-02-07 2015-08-28 Csl Ltd Il-11r binding proteins and uses thereof
CN103965357B (zh) * 2013-12-31 2016-08-17 嘉和生物药业有限公司 一种抗人rankl抗体
CN105497893B (zh) 2015-12-10 2019-02-01 黑龙江省科学院高技术研究院 IL-11单克隆抗体在抑制PI3K/Akt信号通路中的应用
GB201522186D0 (en) 2015-12-16 2016-01-27 Singapore Health Services Pte Ltd And Nat University Of Singapore The Treatment of fibrosis
RU2016125115A (ru) 2016-06-23 2017-12-28 Федеральное государственное бюджетное учреждение науки Институт биологического приборостроения с опытным производством Российской Академии наук (ИБП РАН) Терапевтическое антитело, специфичное к интерлейкину-11, ингибирующее сигналирование через его рецептор, и способ его использования для лечения пациентов
US20180186871A1 (en) 2016-12-16 2018-07-05 Singapore Health Services Pte Ltd. Il-11 antibodies
GB201621439D0 (en) 2016-12-16 2017-02-01 Singapore Health Services Pte Ltd And Nat Univ Of Singapore IL-11Ra Antibodies
RU2016151730A (ru) 2016-12-28 2018-06-29 Федеральное государственное бюджетное учреждение науки Институт биологического приборостроения с опытным производством Российской Академии наук (ИБП РАН) Антитела для лабораторной диагностики концентрации интерлейкина-11
GB201809700D0 (en) 2018-06-13 2018-08-01 Singapore Health Serv Pte Ltd IL-11 antibodies
GB201809699D0 (en) 2018-06-13 2018-08-01 Singapore Health Serv Pte Ltd IL-11 antibodies

Also Published As

Publication number Publication date
WO2018109170A2 (en) 2018-06-21
CA3046848A1 (en) 2018-06-21
JP7175271B2 (ja) 2022-11-18
US20200207847A1 (en) 2020-07-02
CN110337447A (zh) 2019-10-15
GB201621439D0 (en) 2017-02-01
WO2018109170A3 (en) 2018-08-30
TW201829465A (zh) 2018-08-16
JP2020513745A (ja) 2020-05-21
EP3555135A2 (en) 2019-10-23
US20180186872A1 (en) 2018-07-05
KR20190111924A (ko) 2019-10-02
BR112019012343A2 (pt) 2019-11-26
US11078269B2 (en) 2021-08-03
CN110337447B (zh) 2023-05-26
AU2017378107A1 (en) 2019-07-25
EP3555135B1 (en) 2024-04-10

Similar Documents

Publication Publication Date Title
MX2019007021A (es) Anticuerpos il-11ra.
MX2019007020A (es) Anticuerpos il-11.
MX2021006235A (es) Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos.
SG10201803042PA (en) Anti-tim-3 antibodies
IL262497A (en) Anti-il-33 antibodies, compositions, methods and uses thereof
MX2020009649A (es) Anticuerpos monoclonales contra bcma.
MY191581A (en) Anti-pd-1 antibodies
PH12016502142A1 (en) Anti-ptk7 antibody-drug conjugates
PH12017500861A1 (en) Anti-interleukin-33 antibodies and uses thereof
MX2017003478A (es) Anticuerpos anti-fgfr2/3 y metodos para su uso.
SG10201804931QA (en) Anti-cll-1 antibodies and immunoconjugates
PH12017500322A1 (en) Anti-her2 antibodies and immunoconjugates
PH12017500022A1 (en) Carrier-antibody compositions and methods of making and using the same
MY193806A (en) Affinity-oligonucleotide conjugates and uses thereof
MX2017016169A (es) Anticuerpos anti-her2 y metodos de uso.
PH12016501763B1 (en) Multispecific antibodies
SG10201808259TA (en) Anti-jagged1 antibodies and methods of use
MX2016015162A (es) Anticuerpos anti - gpc3 e inmunoconjugados.
WO2017075173A3 (en) Anti-factor d antibodies and conjugates
MX2016004802A (es) Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso.
MX2023006458A (es) Oligosacaridos inmunomoduladores.
GB2576614B (en) Compositions, uses and methods
ZA201803476B (en) Anti-cd22 antibody-maytansine conjugates and methods of use thereof
IL237852A0 (en) Antibodies against amphigoline, medical preparations containing them and their use
GB201804163D0 (en) Uses, compositions and methods